Drugs / MW11
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04478461 | Sep 2020 → Jan 2023 | neoplasm | Mabwell (Shanghai) Bioscience Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MW11 | “This is a phase Ia, single-center, open label, dose escalation clinical study to evaluate the safety, tolerability, pharmacokinetics, immunogenicity and anti-tumor efficacy of...” NCT04478461 ↗ |
| Modality | Monoclonal antibody | “MW11 (a recombinant humanized anti-PD-1 monoclonal antibody)” NCT04478461 ↗ |